The 12th Tianjin International Breast Cancer Conference

The incidence and mortality rate of breast cancer in China is still increasing year by year, and it has now become one of the chief malignant tumors threatening the health of women in China today. The problem of how to further improve patient survival rates has become the main focus of current breast cancer prevention and control.

In order to incorporate the latest research results and development trends in international breast cancer research, we need to explore more targeted strategies for the precise treatment, prevention and control of breast cancer in Asia, and provide an international platform for cooperation in breast cancer prevention and treatment.  

 "The 12th Tianjin International Breast Cancer Conference" was held in Tianjin on August 23rd-24th,2019. Experts and scholars in breast cancer from nearly 10 countries around the world shared their expertise, focusing on breast cancer precision medicine strategy, translational medicine, imaging diagnosis, comprehensive treatment, multidisciplinary collaboration and other aspects of academic exchanges. This included a special discussion on the characteristics of the disease, disease, diagnosis and treatment of breast cancer in Asia. This has served to further promote the cooperation and development of breast cancer diagnosis and treatment in the countries along the Belt and Road Initiatives.

Prof. Guosheng Ren, Chairman of China Anti-Cancer Association Society of Breast Cancer, delivered a speech

Prof. Ping Wang , President of Tianjin Medical University Cancer Institute & Hospital, delivered a speech

Prof. Zhi Yao, Party Secretary of Tianjin Medical University, delivered a speech

Prof. Wei Lu, Party Secretary of Tianjin Medical University Cancer Institute & Hospital(TMUCIH); Profs. Jihui Hao, Kexin Chen, and Bo Xu,Vice Presidents of TMUCIH, attended the Opening Ceremony

Prof.Jin Zhang,Vice Chairman of the China Anti-Cancer Association Society of Breast Cancer/ Vice Director of Tianjin Breast Cancer Research Center for Prevention and Treatment, Tianjin Medical University Cancer  Institute & Hospital(TMUCIH) /Chief of Department of Breast Cancer III, TMUCIH,presided over the Opening Ceremony

To commemorate the outstanding contribution of Professor Xianzhai Jin, the father of Chinese oncology, to human cancer prevention and treatment and breast cancer prevention and treatment, and commemorating Prof. Xianzhai Jin’s founding of China Anti-Cancer Association and the establishment of the first breast cancer oncology unit in the New China and the holding of China's first international conference on oncology and the first international breast cancer conference in Tianjin, China,the conference has set up the “Special Contribution Award of Xianzhai Jin” to be Awarded to the experts who have made outstanding contributions to the prevention and treatment of human breast cancer.

According to Professor Jin Zhang, because of the influence of different susceptibility factors and lifestyles, breast cancer in Chinese and Western populations has different biological characteristics. This also suggests that different strategies should be explored in the screening and treatment of breast cancer in Asia, rather than blindly adopting a "one-size-fits-all" approach to breast cancer patients.

Academician Jinming Yu, President of Shandong Cancer Hospital

Prof. Haraldzur Hausen, the Winner of the 2008 Nobel Prize in Physiology and Medicine

Prof. Zhimin Shao, Fudan University Cancer Hospital

Prof. Binghe Xu, the Cancer Hospital of Chinese Academy of Medical Sciences

Prof.Seigo Nakamura, Showa University, Japan

Prof. Michael Douek, Director of the Department of Surgical Interventional Testing, Royal College, Oxford, UK

Prof. Tony Ng, Head of School of Cancer & Pharmaceutical Sciences, King's College London, UK

Prof.Omar Z. Youssef, President of International Breast Surgery (BSI)

Prof. Woochul Noh, Dean of the National Cancer Center of Korea

Prof. Somashekhar.S.P, Director of Oncology, Manipal Cancer Center, India

With the extensive spread of the concept of early diagnosis and treatment and the continuous advancement of medical technology ,Breast cancer has become one of the solid tumors which has more therapeutic methods available leading to better curative effect. New detection techniques, treatment methods and programs are emerging one after another. The survival time of breast cancer patients is greatly prolonged, and the quality of life is further improved. A new need for cancer patients is a new direction for the diagnosis and treatment of breast cancer by formulating a tailor-made precision diagnosis and treatment strategy.